Metastatic Prostate Cancer

This week’s episode will be focusing on how we met, the future of the podcast, and why we picked heme/onc. This is a very different style of episode and a special once because this month is our 4 year anniversary of Two Onc Docs! And we will back to our regular programming next w ... Show More

We are back with a very special guest Dr. Michael Pishvaian, who is an Associate Professor in GI Oncology at the Johns Hopkins Kimmel Cancer Center, and creator of Tumor Board Tuesday. In part 3, we discuss supportive care in pancreatic cancer, and exciting trials in this space. 

We are back with a very special guest Dr. Michael Pishvaian, who is an Associate Professor in GI Oncology at the Johns Hopkins Kimmel Cancer Center, and creator of Tumor Board Tuesday. In part 2, we will focus on metastatic pancreatic cancer, 1L treatments, maintenance therapy, t ... Show More

New research on prostate cancer screening and diet 

Send us Fan MailNinja Nerds!In this episode of the Ninja Nerd Podcast, Zach and Rob break down the essential clinical and pathophysiologic features of Prostate Cancer, one of the most common malignancies affecting men worldwide.We begin with the epidemiology and risk factors, hig ... Show More

What to look out for in bladder, prostate and renal cancer at this year's meeting. 

Olympic cyclist Sir Chris Hoy is calling for more prostate cancer testing after he was diagnosed with terminal cancer. Prostate cancer can often present without symptoms, and for people like Sir Chris, this can mean it isn't diagnosed until it has spread and become incurable. Unl ... Show More

Thomas Zilli discusses controversies around radiotherapy in prostate cancer. 

About 1 in 8 men will be diagnosed with prostate cancer during their lifetime. Join Lauren Bright Pacheco at the 2024 ASCO Annual Meeting in Chicago, as she investigates the advancements in prostate cancer care.  Dr. Mohammad Atiq shares ways innovative treatments are paving the ... Show More

Prostate cancer diagnostic guidelines aim to minimize over-diagnosis of clinically insignificant prostate cancer (Gleason6/GG1). The clinical question before us is how do we enable the best balance, helping to increase compliance with the biopsy recommendation for patients at hig ... Show More

One in eight men will be diagnosed with prostate cancer, and President Biden’s recent diagnosis has many people asking: Am I at risk? Should I get screened? Dr. Sanjay Gupta breaks down what to know about PSA tests, family history, screening age, and how your diet might factor in ... Show More

Among men aged 15 to 44 years, testicular tumours are the most common cancer diagnosed. And testicular cancer can cause considerable morbidity and mortality. So it is important that we get the diagnosis and management of this condition right. To find out more about this problem a ... Show More